Daclatasvir is a prescription antiviral medication used to treat chronic hepatitis c infection. It belongs to a class of drugs called ns5a replication complex inhibitors that block a viral protein essential for hepatitis c virus replication. By binding to the ns5a protein, Daclatasvir prevents the formation of new viral particles and reduces the viral load in the bloodstream. The drug is administered orally and is absorbed in the gastrointestinal tract where it reaches the liver to exert its antiviral activity. Pharmacodynamically, Daclatasvir acts as a potent allosteric inhibitor, stabilizing the ns5a conformation and halting downstream viral replication steps. Its pharmacological effect is amplified when combined with other direct-acting antivirals that target different stages of the hepatitis c life cycle. This coordinated inhibition leads to sustained virologic response by eliminating persistent infection and preventing relapse.

Daclatasvir is an antiviral medication used to treat chronic hepatitis c infection. It works by inhibiting the replication of the hepatitis c virus. The drug binds to a specific viral protein called ns5a, which is essential for viral assembly and replication. This interaction prevents the virus from multiplying and reduces the amount of virus in the bloodstream. By blocking ns5a, Daclatasvir also enhances the immune system's ability to control the infection. The medication is taken orally and is often combined with other antivirals to achieve a higher cure rate. Its effect leads to sustained virologic response, meaning the virus remains undetectable after treatment ends.

Daclatasvir is generally well tolerated but may cause several side effects. Headache is reported frequently by patients receiving the drug. Fatigue often occurs during treatment. Nausea is a common gastrointestinal symptom. Insomnia can disrupt sleep patterns in some individuals. Skin reactions such as rash or itching may develop. Laboratory tests sometimes show mild reductions in red blood cell counts. These effects are usually mild to moderate and do not require prescription changes.

Daclatasvir may cause mild fatigue in some patients. It can also lead to headache or nausea. Some people experience diarrhea or abdominal discomfort. Elevated liver enzymes have been reported in certain cases. Skin reactions such as rash are occasionally observed. No serious immune-mediated side effects are commonly associated.